NASDAQ:ADMS

Adamas Pharmaceuticals Stock Forecast, Price & News

$4.78

-0.13 (-2.65 %)

(As of 07/30/2021 12:00 AM ET)

Add

Compare

Today's Range

$4.71

▼

$4.97

50-Day Range

$4.78

▼

$5.61

52-Week Range

$2.44

▼

$9.15

Volume132,187 shs

Average Volume203,440 shs

Market Capitalization$197.75 million

P/E RatioN/A

Dividend YieldN/A

Beta2.7

30 days | 90 days | 365 days | Advanced Chart

Receive ADMS News and Ratings via Email

Sign-up to receive the latest news and ratings for Adamas Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

About Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. It offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, as well as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing OFF episodes; and OSMOLEX ER, an extended release tablet to treat Parkinson's disease and drug-induced extrapyramidal reactions in adult patients. The company is also developing ADS-4101, which has completed two Phase 1b studies for treating partial onset seizures in patients with epilepsy. In addition, it offers NAMZARIC and NAMENDA XR, a memantine hydrochloride extended release and donepezil hydrochloride capsules for the treatment of moderate to severe dementia of an Alzheimer's type. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.

Adamas Pharmaceuticals (ADMS) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
July 29, 2021 | finance.yahoo.com

Adamas Pharmaceuticals Inc (ADMS): Hedge Funds Are Snapping Up
July 26, 2021 | finance.yahoo.com

ADMS Aug 2021 5.000 call
July 25, 2021 | ca.finance.yahoo.com

Adamas Announces Issuance of New Patents for GOCOVRI and ADS-4101
July 22, 2021 | finance.yahoo.com

$22.24 Million in Sales Expected for Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) This Quarter
July 19, 2021 | americanbankingnews.com

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Expected to Announce Earnings of -$0.27 Per Share
July 17, 2021 | americanbankingnews.com

Adamas Pharmaceuticals, Inc. Common Stock (ADMS)
July 16, 2021 | nasdaq.com

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Given Consensus Recommendation of "Buy" by Brokerages
July 9, 2021 | americanbankingnews.com

Adamas to Present at Upcoming William Blair Biotech Focus Conference
July 8, 2021 | finance.yahoo.com

If You Had Bought Adamas Pharmaceuticals (NASDAQ:ADMS) Stock A Year Ago, You Could Pocket A 110% Gain Today
July 5, 2021 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ADMS
Previous Symbol
CUSIPN/A
CIK1328143
Webwww.adamaspharma.com
Phone510-450-3500
Employees138
Year FoundedN/A

Sales & Book Value

Annual Sales$74.46 million
Price / Sales2.66
Cash FlowN/A
Price / Cash FlowN/A
Book Value($1.75) per share
Price / Book-2.73

Profitability

EPS (Most Recent Fiscal Year)($2.03)
Net Income$-57,400,000.00
Net Margins-67.26%
Return on EquityN/A
Return on Assets-38.42%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares41,370,000
Market Cap$197.75 million
Next Earnings Date8/5/2021 (Estimated)
OptionableOptionable

MarketRank^™

Overall MarketRank^™

2.40 out of 5 stars

3.4 Analyst's Opinion

Consensus Rating
Adamas Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $10.17, Adamas Pharmaceuticals has a forecasted upside of 112.7% from its current price of $4.78.
Amount of Analyst Coverage
Adamas Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

4.7 Community Rank

Outperform Votes
Adamas Pharmaceuticals has received 400 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Adamas Pharmaceuticals has received 164 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Adamas Pharmaceuticals has received 70.92% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Adamas Pharmaceuticals and other stocks. Vote “Outperform” if you believe ADMS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ADMS will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Adamas Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Adamas Pharmaceuticals does not have a long track record of dividend growth.

3.3 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Adamas Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $42,332.00 in company stock.
Percentage Held by Insiders
18.90% of the stock of Adamas Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
69.82% of the stock of Adamas Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Adamas Pharmaceuticals are expected to grow in the coming year, from ($1.05) to ($0.36) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Adamas Pharmaceuticals is -2.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Adamas Pharmaceuticals is -2.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Adamas Pharmaceuticals (NASDAQ:ADMS) Frequently Asked Questions

Is Adamas Pharmaceuticals a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Adamas Pharmaceuticals in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Adamas Pharmaceuticals stock.
View analyst ratings for Adamas Pharmaceuticals or view top-rated stocks.

What stocks does MarketBeat like better than Adamas Pharmaceuticals?

Wall Street analysts have given Adamas Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Adamas Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Adamas Pharmaceuticals' next earnings date?

Adamas Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Adamas Pharmaceuticals.

How were Adamas Pharmaceuticals' earnings last quarter?

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) announced its quarterly earnings data on Sunday, May, 9th. The specialty pharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.51) by $0.15. The specialty pharmaceutical company had revenue of $19.31 million for the quarter, compared to analysts' expectations of $19.59 million.
View Adamas Pharmaceuticals' earnings history.

How has Adamas Pharmaceuticals' stock price been impacted by COVID-19?

Adamas Pharmaceuticals' stock was trading at $3.05 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ADMS stock has increased by 56.7% and is now trading at $4.78.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for ADMS?

5 equities research analysts have issued 12 month target prices for Adamas Pharmaceuticals' stock. Their forecasts range from $6.00 to $12.50. On average, they expect Adamas Pharmaceuticals' stock price to reach $10.17 in the next year. This suggests a possible upside of 112.7% from the stock's current price.
View analysts' price targets for Adamas Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Adamas Pharmaceuticals' key executives?

Adamas Pharmaceuticals' management team includes the following people:

Mr. Neil F. McFarlane, CEO & Director (Age 48, Pay $1.26M)
Mr. Christopher B. Prentiss, Chief Financial Officer (Age 46, Pay $597.58k) (LinkedIn Profile)
Mr. Vijay Shreedhar Ph.D., Chief Commercial Officer (Age 50, Pay $722.83k) (LinkedIn Profile)
Ms. Sarah Mathieson, Head of Corp. Communications, Patient Advocacy & Engagement
Mr. Dean Hart, Sr. VP of Sales
Dr. Jill M. Jene, Head of Corp. Devel., Strategy , Portfolio Planning & Alliance Management (Age 48)
Mr. Eric C. Schlezinger, Head of HR (Age 54)
Ms. Melissa Masterson, Sr. VP of Commercial Operations & Market Access
Mr. Adrian Quartel M.D., Chief Medical Officer

What is Neil McFarlane's approval rating as Adamas Pharmaceuticals' CEO?

2 employees have rated Adamas Pharmaceuticals CEO Neil McFarlane on Glassdoor.com. Neil McFarlane has an approval rating of 100% among Adamas Pharmaceuticals' employees. This puts Neil McFarlane in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Adamas Pharmaceuticals' key competitors?

Some companies that are related to Adamas Pharmaceuticals include OrganiGram (OGI), IVERIC bio (ISEE), Aclaris Therapeutics (ACRS), RAPT Therapeutics (RAPT), Silence Therapeutics (SLN), Mersana Therapeutics (MRSN), Bicycle Therapeutics (BCYC), VBI Vaccines (VBIV), Akero Therapeutics (AKRO), G1 Therapeutics (GTHX), NRx Pharmaceuticals (NRXP), Pharming Group (PHAR), Avidity Biosciences (RNA), Calliditas Therapeutics AB (publ) (CALT) and Pliant Therapeutics (PLRX).
View all of ADMS's competitors.

What other stocks do shareholders of Adamas Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adamas Pharmaceuticals investors own include Rite Aid (RAD), Sorrento Therapeutics (SRNE), Amarin (AMRN), ACADIA Pharmaceuticals (ACAD), Sangamo Therapeutics (SGMO), Dynavax Technologies (DVAX), TG Therapeutics (TGTX), VBI Vaccines (VBIV), Exelixis (EXEL) and Nabriva Therapeutics (NBRV).

What is Adamas Pharmaceuticals' stock symbol?

Adamas Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMS."

Who are Adamas Pharmaceuticals' major shareholders?

Adamas Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include MAI Capital Management (1.31%) and Fisher Asset Management LLC (0.14%). Company insiders that own Adamas Pharmaceuticals stock include Alfred G Merriweather, Christopher B Prentiss, Martha J Demski, Spyridon Papapetropoulos and Vijay Shreedhar.
View institutional ownership trends for Adamas Pharmaceuticals.

Which institutional investors are buying Adamas Pharmaceuticals stock?

ADMS stock was bought by a variety of institutional investors in the last quarter, including MAI Capital Management, and Fisher Asset Management LLC.
View insider buying and selling activity for Adamas Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Adamas Pharmaceuticals?

Shares of ADMS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Adamas Pharmaceuticals' stock price today?

One share of ADMS stock can currently be purchased for approximately $4.78.

How much money does Adamas Pharmaceuticals make?

Adamas Pharmaceuticals has a market capitalization of $197.75 million and generates $74.46 million in revenue each year. The specialty pharmaceutical company earns $-57,400,000.00 in net income (profit) each year or ($2.03) on an earnings per share basis.

How many employees does Adamas Pharmaceuticals have?

Adamas Pharmaceuticals employs 138 workers across the globe.

What is Adamas Pharmaceuticals' official website?

The official website for Adamas Pharmaceuticals is www.adamaspharma.com.

Where are Adamas Pharmaceuticals' headquarters?

Adamas Pharmaceuticals is headquartered at 1900 POWELL ST. SUITE 1000, EMERYVILLE CA, 94608.

How can I contact Adamas Pharmaceuticals?

Adamas Pharmaceuticals' mailing address is 1900 POWELL ST. SUITE 1000, EMERYVILLE CA, 94608. The specialty pharmaceutical company can be reached via phone at 510-450-3500 or via email at [email protected]

This page was last updated on 8/1/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here